Kymera Therapeutics announced its clinical development plans for 2025, focusing on its oral degrader programs targeting immunological diseases. The company is currently conducting a Phase 1 trial for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback